Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Not long after political candidates pointed to astronomical drug prices on the debate stage, new analysis showed that the average price of new brand-name drugs skyrocketed in the last decade. Current and future politicians linger in a limbo of promises that can’t be immediately acted on. To date, most governmental drug pricing proposals have been delayed or rescinded by the Trump administration. And pharmaceutical industry regulators, too, have been slow to make much progress on drug prices within a Byzantine mire of authorities.

Meanwhile, pharmacy giants are in a feeding frenzy, with transactions like Amgen’s purchase of Celgene’s psoriasis drug clearing a roadblock for Bristol-Myers Squibb’s acquisition of Celgene.

Complete your profile to continue reading and get FREE access to BenefitsPRO.com, part of your ALM digital membership.

Your access to unlimited BenefitsPRO.com content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Critical BenefitsPRO.com information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events.
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com

Already have an account?


Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join BenefitsPRO.com now!

  • Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
  • Exclusive discounts on BenefitsPRO.com and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2020 ALM Media Properties, LLC. All Rights Reserved.